AstraZeneca shares fall 5% on disappointing lung cancer drug trial results

AstraZeneca shares fell more than 5% Tuesday morning, the biggest one-day drop in seven months, after the British pharmaceutical giant announced disappointing lung cancer drug trial results.

The Covid-19 vaccine maker was trading at the bottom of the FTSE 100 and dragged the wider healthcare sector lower after data published Monday showed that its experimental drug did not significantly improve overall survival results for patients.

Share were down 4.9% by 9:43 a.m. London time.

This is a breaking news story. Please check back for updates.

Source

World

India is set to host Russia’s Putin, deepening trade ties, unfazed by punitive U.S. tariffs

December 3, 2025

Russia’s President Vladimir Putin awards India’s Prime Minister Narendra Modi with the Order of St. Andrew the Apostle the First-Called at the Kremlin in Moscow, Russia July 9, 2024. Evgenia Novozhenina | Reuters As India reels under punitive U.S. tariffs over its purchases of Russian oil, New Delhi is all set to host President Vladmir […]

World

Russia ‘ready’ for war with Europe, Putin says, as Ukraine peace talks fail to deliver breakthrough

December 3, 2025

Russian President Vladimir Putin speaks to journalists during his press conference at the VTB Investment Forum ‘Russia Calling!’, on December 2, 2025 in Moscow, Russia. Putin visited an annual forum, hosted by the VTB Group, prior his talk with U.S. special envoy Steve Witkoff. Contributor | Getty Images News | Getty Images Peace talks held […]

World

U.S. pauses all immigration applications from 19 non-European countries

December 3, 2025

Travelers from Latin America and the Caribbean arrive at Miami International Airport. Carl Juste | Miami Herald | Getty Images The Trump administration on Tuesday said it paused all immigration applications, including green card and U.S. citizenship processing, filed by immigrants from 19 non-European countries, citing concerns over national security and public safety. The pause […]